Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 595363, 6 pages
Review Article

Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination

1Research Center for Immunotherapy (FZI), Langenbeckstr. 1, Building 708, 55131 Mainz, Germany
2Biopharmaceutical New Technologies (BioNTech) Corporation, An der Goldgrube 12, 55131 Mainz, Germany
3TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, Germany

Received 23 September 2015; Accepted 15 December 2015

Academic Editor: Steve Pascolo

Copyright © 2015 Mathias Vormehr et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Advances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the efficient targeting of mutated neoantigens for personalized cancer vaccination. Due to their absence during negative selection of T cells and their lack of expression in healthy tissue, tumor mutations are considered as optimal targets for cancer immunotherapy. Preclinical and early clinical data suggest that synthetic mRNA can serve as potent drug format allowing the cost efficient production of highly efficient vaccines in a timely manner. In this review, we describe a process, which integrates next generation sequencing based cancer mutanome mapping, in silico target selection and prioritization approaches, and mRNA vaccine manufacturing and delivery into a process we refer to as MERIT (mutanome engineered RNA immunotherapy).